Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 25 or more amino acid residues in defined sequence
Reexamination Certificate
2007-03-13
2007-03-13
Huff, Sheela J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
25 or more amino acid residues in defined sequence
C530S300000, C530S317000, C530S323000
Reexamination Certificate
active
10160290
ABSTRACT:
The present invention provides peptides and peptidomimetics corresponding to part or to the entirety of the region encompassed by residues 360–386 of human p53, said peptides and peptidomimetics characterized by the ability to activate DNA binding of wild-type p53 and of select tumor-derived p53 mutants. Pharmaceutical compositions of the compounds of the invention and methods of using these compositions therapeutically are also provided.
REFERENCES:
patent: 6169073 (2001-01-01), Halazonetis et al.
patent: 6245886 (2001-06-01), Halazonetis et al.
patent: 6420118 (2002-07-01), Halazonetis et al.
patent: 0 518 650 (1992-12-01), None
patent: WO 94/08241 (1994-04-01), None
patent: WO 94/10306 (1994-05-01), None
patent: WO 94/12202 (1994-06-01), None
patent: WO 95/17213 (1995-06-01), None
Stryer, Biochemistry second edition, p. 13-17, 1981.
Naoko Arai et al., “Immunologically Distinct p53 Molecules Generated by Alternative Splicing.” Molecular and Cellular Biology, vol. 6, No. 9, Sep. 1986, p. 3232-3239.
Coller et al., “Substituting Isoserine for Serine in the Thrombin Receptor Activation Peptide SFLLRN Confers Resistance to Aminopeptidase M-induced Cleavage and Inactivation.”J. Biol. Chem., 268(28):20741-20743 (1993).
Couder et al., “Synthesis and Biological Activities of ψ(CH2NH) Pseudopeptide Analogues of the C-terminal Hexapeptide of Neurotensin,”Internat. J. Peptide&Protein Res., 41(2):181-184 (1993).
DalPozzo et al. “H-Gly-Hisψ(NHCO)Lys-OH. Partially ModifiedRetro-InversoAnalogue of the Growth Factor Glycyl-L-histidyl-I-lysine with Enhanced Enzymatic Stability.”Int. J. Peptide ProteinRres., 41:561-566 (1993).
Hupp et al., “Regulation of the Cryptic Sequence-Specific DNA-Binding Function of p53 by Protein Kinases,”Cold Spring Harbor Symposia on Quantitative Biology. vol. LIX. pp. 195-205 (1994).
Hupp et al., “Small Peptides Activate the Latent Sequence Specific DNA Binding Function of p53.”Cell, 83:237-245 (1995).
Shaw et al., “Regulation of Specific DNA Binding by p53 Evidence for a Role of o-Glycosylation and Charged Residues at the Carboxy-terminus,”Oncogene, 12:921-930 (1996).
Takenaka et al., Regulation of the Sequence-Specific DNA Binding Function of p53 by Protein Kinase C and Protein Phosphatases,:J. Biol. Chem., 270(10):5405-5411 (1995).
Tanigaki et al., “The Peptide Binding Specificity of HLA-B27 Subtypes,”Immunogenetics, 40:192-198 (1994).
Powell et al., Peptide Stability in Drug Development. II. Effect of Single Amino Acid Substitution and Glysosylation on Peptide Reactivity in Human Serum,:Pharmaceutical Research, 10(9):1268-1273 (1993).
Naoko Arai et al., “Immunologically Distinct p53 Molecules Generated by Alternative Splicing.” Molecular and Cellular Biology. vol. 6, No. 9, Sep. 1986, p. 3232-3239.
Brady et al., “Reflections on a Peptide.”Nature,368:692-693 (1994).
Hupp et al., “Allosteric Activation of Latent p53 Tetramers.”Current Biology. 4(10):865-875 (1994).
Wade-Evans et al. “Precise Epitope Mapping of the Murine Transformation-Associated Protein, p53,”EMBO J., 4:699-706 (1985).
Finlay et al., “The p53 Proto-Oncogene Can Act as a Suppressor of Transformation,”Cell, 57:1083-1093 (1989).
Soussi et al , “Structural Aspects of the p53 Protein in Relation to Gene Evolution,”Oncogene. 5:945-952 (1990).
Hupp et al., “Regulation of the Specific DNA Binding Function of p53,”Cell, 71:857-886 (1992).
Hruby, “Conformational and Topographical Consideration in the Design of Biologically Active Peptides.”Biopolymers, 33:1073-1082 (1993).
Hupp et al., “Activation of the Cryptic DNA Binding Function of Mutant Forms of p53.”Nucleic Acids Res., 21:3167-3174 (1993).
Fujiwara et al., “A Retroviral Wild-Type p53 Expression Vector Penetrates Human Lung Cancer Spheroids and Inhibits Growth by Inducing Apoptosis.”Cancer Res., 53:4129-4133 (1993).
Halazonetis et al., “Wild-Type p53 Adopts a ‘Mutant’-like Conformation when Bound to DNA,”EMBO J., 12:1021-1028 (1993).
Halazonetis et al., Conformational Shifts Propagate from the Oligomerization Domain of p53 to its Tetrameric DNA Finding Domain and Restore DNA Binding to Select p53 Mutants.EMBO J., 12:5057-5064 (1993).
Bugg et al., “Drugs by Design,”Sci. Am., 269:92-98 (1993).
Friend, “p53: A Glimpse at the Puppet Behind the Shadow Play,”Science, 265:334-335 (1994).
Cho et al , “Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations,”Science, 265:346-355 (1994).
Clore et al. “High Resolution Structure of the Oligomerization Domain of p53 by Multidimensional NMR,”Science, 265:386-391 (1994).
Speir et al., “Potential Role of Human Cytomegalovirus and p53 Interaction in Coronary Restenosis,”Science, 265:391-394 (1994).
Cox et al., “Xeoapusp53 is Biochemically Similar to the Human Tumour Suppressor Protein p53 and is Induced Upon DNA Damage in Somatic Cells.”Oncogene. 9:2951-2959 (1994).
Jameson et al., “A Rationally Designed CD4 Analogue Inhibits Experimental Allergic Encephalomyelitis,”Nature, 368:744-746 (1994).
Moore, “Designing Peptide Mimetics,”Trends Pharmacol. Sci., 15:124-129 (1994).
Dean, “Recent Advances in Drug Design Methods. Where Will They Lead?”BioEssays, 16:683-687 (1994).
Halazonetis Thanos
Hartwig Wolfgang
Bayer Corporation
Huff Sheela J.
The Wistar Institute
LandOfFree
Peptides and peptidomimetics with structural similarity to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides and peptidomimetics with structural similarity to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides and peptidomimetics with structural similarity to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3729116